Fluvoxamine for Treating Patients with COVID-19

Fluvoxamine — a selective serotonin reuptake inhibitor prescribed for various mental health disorders — has been proposed as a treatment for COVID-19, in part because of its putative anti-inflammatory effect. Observational data and a small randomized trial suggested benefit. Now, this drug has been tested in a placebo-controlled, adaptive platform […]

Read More